跳至主要内容
临床试验/NCT06113315
NCT06113315Enrolling By Invitation不适用

An Observational Study of Sarcoma Patients Treated With Immunotherapy at Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center14 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2023年10月27日最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
入组人数
250
试验地点
14
主要终点
prospectively collect and store blood

研究概览

简要总结

The researchers are doing this study to improve their knowledge about immunotherapy use and how effective it is as a treatment for people with sarcoma by collecting information from participants' medical records who have been treated with immune checkpoint blockade or T-cell receptor-based therapy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Participants must have a histologic diagnosis of sarcoma confirmed by an MSK pathologist.
  • Any prospectively identified patient being treated or to be treated with an immune checkpoint inhibitor, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, or anti-LAG3 inhibitor, either as monotherapy or in combination with additional systemic therapy OR any prospectively identified patient being treated or to be treated with ACT-based treatment including but not limited to lifileucil, Afamitresgene autoleucel, and letetresgene autoleuce o Novel immune checkpoints inhibitors that are developed after submission of this protocol will also be included) Please Note: there is no age requirement. Patients of all ages are eligible to enroll

排除标准

  • Patient unwilling to consent to collection of historical and longitudinal clinicopathologic data in the patient medical record from baseline (the period prior to ICB or ACT initiation), during, and after ICB or ACT treatment

结局指标

主要结局

prospectively collect and store blood

时间窗: up to 5 years

of sarcoma patients treated with ICB or ACT

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验